-
Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC
Friday, March 26, 2021 - 1:49pm | 678Compass Secures 2 New Patents In the midst of a public debate about the right use of patents in the psychedelics sector, Compass Pathways (NASDAQ: CMPS) was granted two new patents by the US Patent and Trademark Office. Compass came under scrutiny last month for applying to a series of...
-
Psyched: Inside A Psilocybin Retreat, CA Bill Would Decriminalize Psychedelics, Revive Buys Psilocybin IP
Monday, March 1, 2021 - 8:39am | 1111Inside of a Legal Psilocybin Wellness Retreat At Benzinga, we do what we say, and we say what we do. This hands-on mentality allowed me to take a week off to experience a legal psilocybin retreat in Jamaica. The active ingredient in “magic mushrooms” is currently being researched by top...
-
MindMed To Buy AI Medicine Company HealthMode For CA$42M
Thursday, February 18, 2021 - 1:39pm | 487MindMed (NEO: MMED) (OTCQB: MMEDF) agreed to buy HealthMode, an artificial intelligence medicine company, in a CA$41.56 million (US$32.5 million) stock and cash deal. The psychedelic biotech company confirmed Thursday it will acquire a digital medicine and therapeutics startup that relies...
-
MindMed Begins First-Ever Clinical Trial On MDMA, LSD Combinations
Wednesday, January 20, 2021 - 10:11am | 471Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...
-
It's Albert Hofmann's Birthday: The Father Of LSD Would Have Turned 115 Today
Monday, January 11, 2021 - 7:00pm | 1075This article was originally published on Microdose Psychedelic Insights and appears here with permission. Albert Hofmann, the famous Swiss scientist best known for discovering the psychedelic drug, LSD (lysergic acid diethylamide), would have turned 115 years old today. Endearingly called...
-
2020 Was The Year of Psychedelics — Here's Why
Monday, December 28, 2020 - 10:02am | 1903While many 2020 memories will be gladly left behind, that's not necessarily the case for psychedelics. There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public...
-
Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace
Saturday, December 19, 2020 - 10:30am | 987Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to...
-
Psyched: MindMed Launches DTx Division, ATAI Closes $125M Series C, Novamind Raises CA$10M
Sunday, November 29, 2020 - 1:02pm | 791Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million). Last week, the company confirmed that it successfully inked a definitive amalgamation agreement with Hinterland...
-
Psyched: Oregon Legalizes Psilocybin, Washington DC Decriminalizes Psychedelics, Cybin And Entheon To Go Public
Saturday, November 7, 2020 - 6:47pm | 794Oregon has become the first state in US history to set up a program that regulates psilocybin, the active psychedelic ingredient in “magic mushrooms.” Measure 109 was approved by 55.8% of voters in a ballot vote on Election Day. The measure creates a state-licensed psilocybin-...
-
Oregon Becomes First US State To Decriminalize Drug Possession, Begins Psilocybin Program
Wednesday, November 4, 2020 - 9:43am | 705Voters in Oregon have approved two measures that mark an unprecedented change in the history of U.S. drug policy. Measure 110, which passed with 58.8% positive votes, decriminalizes the possession of small amounts of all illegal drugs. It also creates a support program for drug abuse...
-
Psyched: Field Trip Debuts On CSE, MindMed Teams Up With NYU, Zuckerberg Backs Decriminalization
Saturday, October 10, 2020 - 11:25am | 500Field Trip Trades On CSE On Tuesday, common shares of Field Trip Health began trading on the CSE under the symbol FTRP. The psychedelics company, which has operations in Canada, the U.S. and Jamaica, went public through a reverse take-over with Canadian oil and gas explorer Newton Energy Corp...
-
'Psyched': Field Trip Unveils Novel Compound, Numinus Begins Magic Mushroom Production
Saturday, October 3, 2020 - 11:59am | 617Field Trip Psychedelics Inc. announced Tuesday the successful synthesis of FT-104, a novel compound that is believed to have psychedelic capabilities. The conclusion comes after in-vitro and in-vivo tests confirmed that FT-104 interacts with the 5HT2A receptor, which is the main antagonist targeted...
-
Psyched: Compass Joins Nasdaq, Field Trip Goes Public, MindMed Begins Trials, ATAI Launches MDMA Subsidiary
Friday, September 4, 2020 - 8:51am | 1225Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...
-
'Psyched': Silo Wellness To Go Public, MindMed Adds DMT To Research Portfolio, Champignon Closes $11M Raise, Mydecine Launches New Research Partnership
Saturday, June 20, 2020 - 3:47pm | 1123Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Silo Wellness To Go Public With Reverse Takeover Of Yukoterre Resources Oregon-...
-
MindMed To Include MDMA to Research Portfolio
Wednesday, May 27, 2020 - 7:36pm | 284Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement with the University...